Decision Resources, Inc. 社 調査資料リスト
このページは Decision Resources, Inc.社のレポートを出版日順に随時掲載しております。
| Decision Resources, Inc. について |
 |
ディシジョン・リソーシズ社は世界の医薬品市場及び新薬開発について
分析・評価を行い、世界のトップ製薬関連企業にアドバイザリー・サービスを
提供するインターナショナル・コンサルティング会社です。
|
 | |  |
 |
| 学術機関におけるバイオマーカー研究の産業利用 |
|
Harnessing Biomarker Research in Academic Institutions for Use in Industry
出版日 : 2008/04 | 商品コード : 64730 |
| COPD併存疾患の治療：全身性抗炎症薬の市場機会 |
|
Treating COPD Comorbidities: A Market Opportunity for Systemic Anti-Inflammatory Agents?
出版日 : 2008/03 | 商品コード : 64183 |
| Target Product Profile：II型糖尿病 |
|
Target Product Profiles: Physician Insights on Key Attributes - Type 2 Diabetes, A weight-neutral oral antidiabetic drug for the treatment of type 2 diabetes
出版日 : 2008/03 | 商品コード : 65857 |
| Target Product Profile：クローン病 |
|
Target Product Profiles: Physician Insights on Key Attributes - Crohn's Disease, A parenterally dosed therapy that induces closure and healing of fistulas in a greater percentage of Crohn's disease patients than infliximab does.
出版日 : 2008/03 | 商品コード : 65850 |
| Target Product Profile：タムスロシンより性的副作用の発症率の低い良性前立腺肥大症治療薬の開発 |
|
Target Product Profiles: Physician Insights on Key Attributes - Benign Prostatic Hyperplasia, A drug with lower incidence of sexual side effects than tamsulosin for the treatment of benign prostatic hyperplasia.
出版日 : 2008/03 | 商品コード : 65841 |
| Target Product Profile：乾癬 |
|
Target Product Profiles: Physician Insights on Key Attributes - Psoriasis, A systemic agent that induces 75% improvement in PASI scores at 12 weeks in at least 30% more patients than etanercept for the treatment of psoriasis.
出版日 : 2008/03 | 商品コード : 65851 |
| Target Product Profile：急迫性尿失禁 |
|
Target Product Profiles: Physician Insights on Key Attributes - Urge Urinary Incontinence
出版日 : 2008/03 | 商品コード : 65848 |
| Target Product Profile：軽度認知障害の薬剤開発 |
|
Target Product Profiles: Physician Insights on Key Attributes - Mild Cognitive Impairment, A therapy that improves ADAS-cog score from baseline at 12 months for the treatment of mild cognitive impairment.
出版日 : 2008/03 | 商品コード : 65838 |
| Target Product Profile：結腸癌（ステージ3） |
|
Target Product Profiles: Physician Insights on Key Attributes - Colon Cancer (Stage III), A therapy that improves disease-free survival over FOLFOX4 at three years for the treatment of stage III colon cancer
出版日 : 2008/03 | 商品コード : 65860 |
| Target Product Profile：結腸直腸癌（ステージ4）の薬剤開発 |
|
Target Product Profiles: Physician Insights on Key Attributes - Colorectal Cancer (Stage IV), A therapy that improves median overall survival better than the IFL plus bevacizumab regimen for the first-line treatment of stage IV colorectal cancer
出版日 : 2008/03 | 商品コード : 65861 |
| Target Product Profile：高血圧症向け治療薬の開発 |
|
Target Product Profiles: Physician Insights on Key Attributes: Hypertension - An oral drug that reduces left ventricular mass index significantly more than valsartan
出版日 : 2008/03 | 商品コード : 65830 |
| Target Product Profile：心筋梗塞後症候群治療薬の薬剤開発 |
|
Target Product Profiles: Physician Insights on Key Attributes - Post-Myocardial Infarction, A therapy that, combined with aspirin, causes less major bleeding than the combination of clopidogrel and aspirin for the treatment of postmyocardial infarction.
出版日 : 2008/03 | 商品コード : 65832 |
| Target Product Profile：進行性膵癌の治療薬の開発 |
|
Target Product Profiles: Physician Insights on Key Attributes - Pancreatic Cancer (Advanced), An emerging therapy that improves median overall survival better than the gemcitabine plus erlotinib regimen for the treatment of advanced pancreatic cancer
出版日 : 2008/03 | 商品コード : 65871 |
| Target Product Profile：双極性障害 |
|
Target Product Profiles: Physician Insights on Key Attributes - Bipolar Disorder, A therapy that carries a lower risk of weight gain than quetiapine and has both antimanic and antidepressant effects for the treatment of bipolar disorder.
出版日 : 2008/03 | 商品コード : 65835 |
| Target Product Profile：大うつ病の薬剤開発 |
|
Target Product Profiles: Physician Insights on Key Attributes - Major Depressive Disorder, A therapy that can prevent recurrence of major depressive disorder in a greater percentage of patients than venlafaxine XR does at one year.
出版日 : 2008/03 | 商品コード : 65837 |
| Target Product Profile：糖尿病性神経症治療薬の開発 |
|
Target Product Profiles: Physician Insights on Key Attributes - Diabetic Neuropathy, An agent offering pain relief superior to that of pregabalin
出版日 : 2008/03 | 商品コード : 65843 |
| Target Product Profile：末梢血管疾患治療薬の薬剤開発 |
|
Target Product Profiles: Physician Insights on Key Attributes - Peripheral Arterial Disease - A therapy that reduces the need for revascularization by more than 20% for the treatment of peripheral arterial disease (intermittent claudication).
出版日 : 2008/03 | 商品コード : 65831 |
| Target Product Profile：卵巣癌 |
|
Target Product Profiles: Physician Insights on Key Attributes - Ovarian Cancer (Advanced), An agent or regimen that offers increased median overall survival compared with paclitaxel/carboplatin for the treatment of advanced ovarian cancer
出版日 : 2008/03 | 商品コード : 65866 |
| Target Product Profiles：市中肺炎 |
|
Target Product Profiles: Physician Insights on Key Attributes - Community-Acquired Pneumonia, An antibiotic with targeted activity against respiratory pathogens that does not affect bowel flora for the treatment of community-acquired pneumonia.
出版日 : 2008/03 | 商品コード : 65853 |
| Target Product Profiles：脂質異常症 - HDLを上昇させる薬剤 |
|
Target Product Profiles: Physician Insights on Key Attributes - Dyslipidemia, An HDL-raising drug that has a lower discontinuation rate than extended-release (ER) niacin for the treatment of dyslipidemia.
出版日 : 2008/03 | 商品コード : 65855 |
| Target Product Profiles：肥満症 ‐より減量に有効な治療 |
|
Target Product Profiles: Physician Insights on Key Attributes - Obesity, A therapy that is more effective than orlistat at inducing weight loss for the treatment of obesity
出版日 : 2008/03 | 商品コード : 65856 |
| Target Product Profiles：不眠症 |
|
Target Product Profiles: Physician Insights on Key Attributes - Insomnia, A hypnotic that is free of next-day residual effects for the treatment of insomnia
出版日 : 2008/03 | 商品コード : 65836 |
| 自己免疫疾患の新たな治療戦略 |
|
What Strategies Will Yield Novel Treatments for Autoimmune Disease?
出版日 : 2008/03 | 商品コード : 63873 |
| 創薬市場の情勢：新薬開発の戦略概要 |
|
Navigating the Drug Discovery Landscape: A Strategic Overview of Pharmaceutical R&D
出版日 : 2008/03 | 商品コード : 64364 |
| 臓器移植慢性拒絶反応：待たれる改良型治療法の機会 |
|
Chronic Organ Transplant Rejection: Opportunities Await Improved Therapies
出版日 : 2008/03 | 商品コード : 63734 |
| 糖尿病性腎症治療薬の開発動向 |
|
Target Product Profiles: Physician Insights on Key Attributes - Diabetic Nephropathy, A therapy that is more effective than irbesartan in inducing regression from microalbuminuria to normoalbuminuria for the treatment of diabetic nephropathy
出版日 : 2008/03 | 商品コード : 65842 |
| 薬理ゲノムの動向 |
|
How to Get Ahead with Pharmacogenomics
出版日 : 2008/03 | 商品コード : 63869 |
| ブランドと戦略：非定型抗精神病薬 |
|
Brands & Strategies: Atypical Antipsychotics
出版日 : 2008/02 | 商品コード : 65293 |
| 画像診断市場：最近の進化と将来動向 |
|
Diagnostic Imaging Market: Recent Advances and Future Trends
出版日 : 2008/02 | 商品コード : 62851 |
| 米国における薬価および償還動向 |
|
Pharmaceutical Pricing and Reimbursement in the United States, 2008
出版日 : 2008/02 | 商品コード : 62852 |
| 2007年第4四半期における薬価、償還、処方動向 |
|
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Fourth Quarter of 2007
出版日 : 2008/01 | 商品コード : 62158 |
|
これ以外の商品に関しては、左側の商品カテゴリ、サイト内検索よりお探しいただくか、お問い合わせページより営業担当までお問い合わせください。
他の調査会社・出版社につきましては調査会社・出版社一覧をご覧下さい。
|
FAQ